News > Lupin gets USFDA nod for generic drugs to treat HIV infection
Lupin gets USFDA nod for generic drugs to treat HIV infection
16/01/2023 03:02 PM | Click to read full article
Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in the treatment of HIV infection, in an exchange filing. The tentative approval granted by the US Food and Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
